The underlying molecular mechanisms of GB1 appear to involve the suppression of NLRP3 inflammasome activation, reduction in pro-inflammatory mediators, and the mitigation of DSS-induced ulcerative colitis. Here, GABBR1 is linked to ulcerative colitis.